TransNAT: Transforming delivery, safety and efficacy of nucleic acid therapeutics: from intracellular uptake to targeting brain and muscle.

TransNAT：改变核酸疗法的递送、安全性和有效性：从细胞内摄取到靶向大脑和肌肉。

• 批准号: MR/X008029/1
• 负责人: Matthew Wood
• 金额: $ 1035.53万
• 依托单位: University of Oxford
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2022
• 资助国家: 英国
• 起止时间: 2022 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FX008029%2F1
• 关键词: TransNAT; Transforming; delivery; safety; efficacy

Nucleic acid therapies (NATs) are genetic medicines that address the root cause of disease and have the potential to transform healthcare and provide life changing solutions for numerous areas of unmet need. Neurological, neuromuscular and cardiovascular diseases in particular devastate lives and create a very significant economic and social burden across the entire global population. While NATs have begun to be a reality over the last decade with multiple medicines being approved for use in the US and Europe many challenges remain particularly for diseases outside the liver and for those not easily addressed by local drug delivery solutions. Moreover, recent clinical trial results indicate that safety considerations should be addressed in parallel with the development of delivery solutions. The challenge of NAT delivery put simply is to deliver the drug effectively across the cell membrane into the appropriate sub-cellular compartment at a sufficient concentration required for activity in the absence of significant safety signals - so called 'productive' delivery. Our proposed solution is therefore to understand the requirements for productive delivery of NATs and to exploit this knowledge base for the development of NAT conjugates - our technical solution. Building on extensive experience of our consortium of academic and industry scientists, we will take two independent approaches to NAT conjugates, where delivery agents are directly chemically attached to the NAT drug. First, we will study and optimise lipid conjugates, where a range of lipid entities are directly attached to the NAT via a series of chemical linkers with different properties. In the first instance the NAT is one targeting a common gene of no therapeutic relevance. Our second approach of high potential will be to study and optimise antibody conjugates, where an antibody (or antibody fragment or antibody derived peptide) that binds to a specific cell membrane ligand is conjugated chemically again via chemical linkers. In each case, we will have starting points with conjugates that have already emerged through the work of consortium members, and in the case of antibodies we will have two independent approaches for identifying and prioritising new ligands for antibody targeting, again building on pre-existing work in the consortium. Our extensive chemistry capabilities will generate conjugate materials and control compounds for study and first step of which will be extensive in vitro studies in cells to develop mechanism-based knowledge on productive cell uptake allowing us to select lead compounds for more detailed study based on cell uptake/efficacy/safety properties, and to iterate compound structure and chemistry based on new knowledge, know-how and data generated. Further study will comprise translational studies in ex vivo human model systems based on human cells and stem cells and also based on human three dimensional organ like systems that provide cell diversity and architectural arrangements more closely mimicking human tissues. Further translational studies in established and new rodent models will allow delivery to cells and tissues of brain, heart and muscle to be studied in detail at singe cell resolution permitting cell/tissue biodistribution to be correlated with efficacy and safety measures. Finally, a small number of lead NAT compounds will be studied in disease models related to Huntington's disease and muscular dystrophy. We will maximise the potential of data by analysing and integrating across the programme and implementing machine-learning approaches to exploit our data. We will deliver fundamental knowledge, know-how, data and IP on productive uptake and novel lipid/antibody NATs of high therapeutic potential for further study. We will also engage the broader NAT community via reports/meetings/conferences and develop training opportunities, all of the above working in close collaboration with the NATA Hub.

核酸疗法（NAT）是一种基因药物，可以解决疾病的根本原因，并有可能改变医疗保健，为许多未满足需求的领域提供改变生活的解决方案。神经、神经肌肉和心血管疾病，特别是神经系统疾病，严重影响生命，给全球人口造成非常严重的经济和社会负担。虽然NAT在过去十年中已开始成为现实，多种药物已被批准在美国和欧洲使用，但仍存在许多挑战，特别是对于肝脏以外的疾病以及那些不易通过当地药物递送解决方案解决的疾病。此外，最近的临床试验结果表明，安全性考虑应与递送溶液的开发并行解决。简单地说，NAT递送的挑战是在没有显著安全信号的情况下以活性所需的足够浓度将药物有效地穿过细胞膜递送到适当的亚细胞区室中-所谓的“生产性”递送。因此，我们提出的解决方案是了解NAT的生产交付的要求，并利用这一知识库开发NAT共轭物-我们的技术解决方案。基于我们的学术和工业科学家联盟的丰富经验，我们将采取两种独立的NAT缀合物方法，其中递送剂直接化学连接到NAT药物。首先，我们将研究和优化脂质缀合物，其中一系列脂质实体通过一系列具有不同性质的化学接头直接连接到NAT。在第一种情况下，NAT是靶向无治疗相关性的共同基因的NAT。我们的第二种高潜力的方法将是研究和优化抗体缀合物，其中与特定细胞膜配体结合的抗体（或抗体片段或抗体衍生肽）通过化学接头再次化学缀合。在每种情况下，我们将以通过联盟成员的工作已经出现的缀合物为起点，并且在抗体的情况下，我们将有两种独立的方法来识别和优先考虑用于抗体靶向的新配体，再次建立在联盟中已有的工作基础上。我们广泛的化学能力将产生用于研究的缀合物材料和对照化合物，其中第一步将是在细胞中进行广泛的体外研究，以开发关于生产性细胞摄取的基于机制的知识，使我们能够基于细胞摄取/功效/安全性特性选择先导化合物进行更详细的研究，并基于新知识，专有技术和产生的数据来验证化合物结构和化学。进一步的研究将包括基于人细胞和干细胞的离体人模型系统中的转化研究，以及基于提供更接近模拟人组织的细胞多样性和结构布置的人三维器官样系统的转化研究。在已建立和新的啮齿动物模型中进行的进一步转化研究将允许以单细胞分辨率详细研究向脑、心脏和肌肉的细胞和组织的递送，从而允许细胞/组织生物分布与疗效和安全性措施相关。最后，将在与亨廷顿病和肌营养不良症相关的疾病模型中研究少量的铅NAT化合物。我们将通过分析和整合整个计划，并实施机器学习方法来利用我们的数据，最大限度地发挥数据的潜力。我们将提供基础知识，专有技术，数据和IP的生产性摄取和新的脂质/抗体NAT的高治疗潜力的进一步研究。我们还将通过报告/会议/大会吸引更广泛的NAT社区，并开发培训机会，所有上述工作都与NATA Hub密切合作。